BACKGROUND: Vincristine is one of the cornerstones of the treatment of children with acute lymphoblastic leukaemia (ALL). Constipation, and peripheral and central neurotoxicities are the most common side effects. A comparative study exploring vincristine toxicity in individual patients receiving vincristine with and without azoles, however, is lacking. METHODS: In total, 20 paediatric patients with de novo ALL were included. In each patient, vincristine toxicity in the period with and without azole co-medication was retrospectively graded according to the US National Cancer Institute toxicity scale. Statistical analysis was performed using the Wilcoxon signed rank test and McNemar's test. RESULTS: Patients receiving vincristine in combination with azole treatment experienced significantly more constipation and peripheral neurotoxicity (P = 0.001 and P < 0.001, respectively). Vincristine-induced CNS toxicity was only seen in patients (30%) receiving vincristine in combination with azole treatment. CONCLUSIONS: Vincristine toxicity is significantly enhanced when combined with azole treatment and can even be life threatening. Therefore, we advise avoidance of the combination of azole and vincristine treatments in patients with ALL.
BACKGROUND:Vincristine is one of the cornerstones of the treatment of children with acute lymphoblastic leukaemia (ALL). Constipation, and peripheral and central neurotoxicities are the most common side effects. A comparative study exploring vincristinetoxicity in individual patients receiving vincristine with and without azoles, however, is lacking. METHODS: In total, 20 paediatric patients with de novo ALL were included. In each patient, vincristinetoxicity in the period with and without azole co-medication was retrospectively graded according to the US National Cancer Institute toxicity scale. Statistical analysis was performed using the Wilcoxon signed rank test and McNemar's test. RESULTS:Patients receiving vincristine in combination with azole treatment experienced significantly more constipation and peripheral neurotoxicity (P = 0.001 and P < 0.001, respectively). Vincristine-induced CNS toxicity was only seen in patients (30%) receiving vincristine in combination with azole treatment. CONCLUSIONS:Vincristinetoxicity is significantly enhanced when combined with azole treatment and can even be life threatening. Therefore, we advise avoidance of the combination of azole and vincristine treatments in patients with ALL.
Authors: Brad Moriyama; Stacey A Henning; Janice Leung; Oluwaseun Falade-Nwulia; Paul Jarosinski; Scott R Penzak; Thomas J Walsh Journal: Mycoses Date: 2011-11-29 Impact factor: 4.377
Authors: John H Carter; Jennifer L Lenahan; Gisele E Ishak; J Russell Geyer; Jessica Pollard; Janet A Englund Journal: Pediatr Blood Cancer Date: 2014-11-18 Impact factor: 3.167
Authors: Johan Nicolaï; Louise Thevelin; Qi Bing; Bruno Stieger; Hugues Chanteux; Patrick Augustijns; Pieter Annaert Journal: Pharm Res Date: 2017-08-21 Impact factor: 4.200